Phase I trial of weekly paclitaxel in advanced lung cancer.

@article{Akerley1998PhaseIT,
  title={Phase I trial of weekly paclitaxel in advanced lung cancer.},
  author={Wallace L. Akerley and Michael Glantz and Hak Choy and V P Rege and Sundaresan Sambandam and Plakyil Joseph and Lorrin Yee and Biana Rodrigues and Phoebe Wingate and Luis Le{\'o}ne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 1},
  pages={153-8}
}
PURPOSE We conducted a phase I study in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum-tolerated dose (MTD) of paclitaxel using an extended weekly schedule. PATIENTS AND METHODS Patients with stage IIIB/IV NSCLC were treated with paclitaxel administered weekly over 3 hours for 6 weeks of an 8-week… CONTINUE READING